Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Barrington Research Downgrades Haemonetics (HAE) to Market Perform
February 7, 2017 9:33 AM ESTBarrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform and removed its price target (prior $41.00).
For an analyst ratings summary and ratings history on Haemonetics click here. For more ratings news on Haemonetics click here.
Shares of Haemonetics closed at $38.00 yesterday.
... More